Informace o publikaci
Better treatment response is associated with lenalidomide 25 mg once-daily vs. 25 mg every-other-day in relapsed/refractory multiple myeloma
| Autoři | |
|---|---|
| Rok publikování | 2011 |
| Druh | Konferenční abstrakty |
| Citace | |
| Popis | Lenalidomide is active and generally well-tolerated in relapsed/refractory myeloma. These results support the approved 25 mg once-daily dosing of lenalidomide on days 1- 21 of a 28 day cycle in patients with relapsed/refractory multiple myeloma and indicate that every-other-day dosing compromises response with no significant difference in tolerability. |